IPHA vs VALN
Innate Pharma SA and Valneva SE, side by side — 7 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | IPHA | VALN |
|---|---|---|
| Revenue | €9.0M | €174.7M |
| Net income | €-49.2M | €-115.2M |
| Gross margin | — | 38.7% |
| Net margin | −546.1% | −66.0% |
| Return on equity | — | — |
| Diluted EPS | −€0.55 | −€0.68 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | €-52.9M | €-57.3M |
| Equity | — | — |
| Net debt / equity | — | — |
| Current ratio | 1.27× | 2.38× |
| Revenue CAGR 5y | −33.6% | 9.6% |
| Profit CAGR 5y | — | — |
VALN bills 19.4× the revenue of IPHA, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
7 years side by side
| Fiscal year | IPHA | VALN |
|---|---|---|
| FY2025 | €9.0M | €174.7M |
| FY2024 | €20.1M | €169.6M |
| FY2023 | €61.6M | €153.7M |
| FY2022 | €57.7M | €361.3M |
| FY2021 | €24.7M | €348.1M |
| FY2020 | €69.8M | €110.3M |
| FY2019 | €85.4M | €126.2M |
Net income by year
Bottom line
| Fiscal year | IPHA | VALN |
|---|---|---|
| FY2025 | €-49.2M | €-115.2M |
| FY2024 | €-49.5M | €-12.2M |
| FY2023 | €-7.6M | €-101.4M |
| FY2022 | €-58.1M | €-143.3M |
| FY2021 | €-52.8M | €-73.4M |
| FY2020 | €-64.0M | €-64.4M |
| FY2019 | €-20.8M | €-811,000 |
Advertisement
AdSense · Rectangle 336×280
More in this industry